The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Needham: Maintaining a "buy" rating on Immuneering ( Immuneering Corp. Class A(IMRX.US) ), while raising the price target from $11 to $18.

Jefferies: Maintaining a "buy" rating on Celldex Therapeutics ( Celldex Therapeutics, Inc.(CLDX.US) ), while raising the price target from $90 to $100.

Maxim Group: Upgrades Akari Therapeutics ( Akari Therapeutics Plc Sponsored ADR(AKTX.US) ) to "Buy", with a target price of $30.

Maxim Group: Initial rating for Rein Therapeutics ( Rein Therapeutics, Inc(RNTX.US) ) stock at "Buy", with a target price of $4.

Maxim Group: Maintaining a "buy" rating on Cloudastructure ( Cloudastructure (CSAI.US) ), while lowering the price target from $4 to $1.5.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
Immuneering Corp. Class A(IMRX.US)	to lift	$18.0	$4.29	319.58%	Needham
Celldex Therapeutics, Inc.(CLDX.US)	to lift	$100.0	$35.42	182.33%	富瑞
Akari Therapeutics Plc Sponsored ADR(AKTX.US)	to lift	$30.0	$10.66	181.43%	Maxim Group
NEBIUS(NBIS.US)	to lift	$410.0	$182.62	124.51%	Northland Capital Markets
Trevi Therapeutics(TRVI.US)	to lift	$31.0	$16.77	84.85%	B. Riley Securities
Rein Therapeutics, Inc(RNTX.US)	Initial classification	$4.0	$0.844	373.93%	Maxim Group
Cloudastructure (CSAI.US)	cut	$1.5	$0.2871	422.47%	Maxim Group
OnKure Therapeutics, Inc. Class A(OKUR.US)	cut	$21.0	$4.12	409.71%	HC Wainwright & Co.
Cipher Mining(CIFR.US)	cut	$47.0	$20.54	128.82%	Morgan Stanley
Albemarle Corporation(ALB.US)	cut	$245.0	$118.2	107.28%	Truist Securities

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Barclays: Maintaining an "overweight" rating on Credo Technology Group Credo Technology(CRDO.US) , while raising its price target from $260 to $300.

Oppenheimer: Maintaining an "outperform" rating for Datadog ( Datadog(DDOG.US) ) stock, while raising the price target from $220 to $300.

Bernstein: Maintaining an "outperform" rating for Robinhood Markets ( Robinhood(HOOD.US) ), while raising the price target from $130 to $160.

Evercore ISI Group: Maintaining its "Outperform Market" rating for Lam Research Lam Research Corporation(LRCX.US) ) stock, while raising its price target from $300 to $355.

Morgan Stanley: Maintaining a "market-matched weight" rating for Intel ( Intel Corporation(INTC.US) ), while raising its price target from $73 to $75.

First Coverage

HSBC: Apollo Global Management Apollo Global Management Inc(APO.US) ) stock has a preliminary "buy" rating, with a target price of $145.

BMO Capital: Ralliant ( Ralliant Corporation(RAL.US) ) initial rating at "Market Match", with a target price of $78.

Goldman Sachs: Versigent ( Versigent PLC(VGNT.US) ) has a preliminary "buy" rating on its stock, with a target price of $48.

reduction

UBS: Maintaining a "buy" rating on Disney ( Walt Disney Company(DIS.US) ) stock, while lowering the price target from $138 to $133.

Stifel: Maintaining a "buy" rating on IBM IBM Corp(IBM.US) ) stock, while lowering the price target from $290 to $235.

DA Davidson: Maintaining a "buy" rating on ServiceNow ServiceNow, Inc.(NOW.US) stock, while lowering the price target from $190 to $170.

RBC Capital: Maintaining a "sector-match" rating for Verizon ( Verizon Communications Inc.(VZ.US) ), while lowering its price target from $48 to $46.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.